首页> 外文期刊>Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation >Percutaneous coronary intervention versus medical therapy for chronic total coronary occlusions: a?systematic review and meta-analysis of randomised trials
【24h】

Percutaneous coronary intervention versus medical therapy for chronic total coronary occlusions: a?systematic review and meta-analysis of randomised trials

机译:经皮冠状动脉干预与医疗治疗慢性总冠状动脉闭塞:a?系统评价和随机试验的荟萃分析

获取原文
           

摘要

Background The results of chronic total occlusion percutaneous coronary intervention (CTO-PCI) trials are inconclusive. Therefore, we studied whether CTO-PCI leads to improvement of clinical endpoints and patient symptoms when combining all available randomised data. Methods and results This meta-analysis was registered in PROSPERO prior to starting. We performed a literature search and identified all randomised trials comparing CTO-PCI to optimal medical therapy alone (OMT). A total of five trials were included, comprising 1790 CTO patients, of whom 964 were randomised to PCI and 826 to OMT. The all-cause mortality was comparable between groups at 1?year [risk ratio (RR) 1.70, 95% confidence interval (CI) 0.50–5.80, p?=?0.40] and at 4?year follow-up (RR 1.14, 95% CI 0.38–3.40, p?=?0.81). There was no difference in the incidence of major adverse cardiac events (MACE) between groups at 1 year (RR 0.69, 95% CI 0.36–1.33, p?=?0.27) and at 4 years (RR 0.85, 95% CI 0.60–1.22, p?=?0.38). Left ventricular function and volumes at follow-up were comparable between groups. However, the PCI group had fewer target lesion revascularisations (RR 0.28, 95% CI 0.15–0.52, p??0.001) and was more frequently free of angina at 1?year follow-up (RR 0.65, 95% CI 0.50–0.84, p?=?0.001), although the scores on the subscales of the Seattle Angina Questionnaire were comparable. Conclusion In conclusion, in this meta-analysis of 1790 CTO patients, CTO-PCI did not lead to an improvement in survival or in MACE as reported at long-term follow-up of up to 4 years, or to improvement of left ventricular function. However, CTO-PCI resulted in less angina and fewer target lesion revascularisations compared to OMT.
机译:背景技术慢性总闭塞经皮冠状动脉介入(CTO-PCI)试验的结果不确定。因此,我们研究了CTO-PCI是否会在结合所有可用的随机数据时导致改善临床终点和患者症状。方法和结果在开始之前在Prospero注册了该元分析。我们进行了文献搜索,并鉴定了所有随机试验,将CTO-PCI与单独的最佳医疗疗法进行比较(OMT)。包含5项试验,包含1790名CTO患者,其中964名将其随机化为PCI和826至OMT。全因死亡率在1年的群体之间相当?[风险比(RR)1.70,95%置信区间(CI)0.50-5.80,p?=?0.40]和4年后续(RR 1.14, 95%CI 0.38-3.40,P?= 0.81)。在1年内的主要不良心脏事件(MACE)发生率没有差异(RR 0.69,95%CI 0.36-1.33,p?= 0.27),4年(RR 0.85,95%CI 0.60- 1.22,p?=?0.38)。左心室功能和随访中的体积在组之间是可比的。然而,PCI组的靶病变血运重建率较少(RR 0.28,95%CI 0.15-0.52,P?0.001),更频繁地在1?年后续随访(RR 0.65,95%CI 0.50 -0.84,p?=?0.001),虽然西雅图心绞痛问卷的分数相当。结论总之,在该荟萃分析的1790年CTO患者中,CTO-PCI并未导致生存或术士的改善,如长期随访时间为长期随访,或改善左心室功能。然而,与OMT相比,CTO-PCI导致肺结气较少和较少的靶病变血管体外致血管化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号